IceCure Medical today said it received FDA breakthrough device designation for its ProSense cryoablation system.
ProSense is a liquid nitrogen-based cryoablation system that is a minimally invasive treatment for cancer tumors. It is designed for use in the treatment of TI invasive breast cancer or in patients not suitable for surgical alternatives for treating breast cancer.